ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has released the interim data from its phase-2a clinical trials of CMX157. The trial is a head-to-head study, against Viread, in patients suffering from hepatitis-B. As per reports from the company, the data has so far been positive, with CMX157 demonstrating a 99% reduction in viral load. Although the trial contained patients taking 5mg and 10mg cohorts, the interim data was reported from the 10mg population only.

CTRV noted that the trials had been conducted for a period of 14-days, with patients being orally administered 25mg of CMX157 per day. As a control group, two patients were also administered 300mg of Viread. In its interim report, the company noted that CMX157 achieved a 99% decline in HBV viral load, which was comparable to those being treated by Viread. It should be noted here that similar results had been obtained, but at 1/12th the dose of Viread.

The CEO of ContraVir, James Sapirstein, expressed his excitement at the results, stating that it demonstrates the potential of CMX157 in becoming a cure for HBV. He pointed out that it was the company’s unique liver targeting mechanism that was responsible for the favorable safety and efficacy profile of the drug, at low dosage. Mr. Sapirstein also hinted at the possibility of developing the drug to become a backbone for combination therapies, against HBV, in the future.

CTRV is scheduled to attend the “15th Annual BIO Investor Forum”, due to be held on October 18-19, 2016, in San Francisco. The company would be represented by its CEO, who would provide the attendees with a business overview, in his presentation. Mr. Sapirstein would also be available after the conference, for one-on-one meetings, with investors interested in the company. It should be noted here that the aforementioned results would provide the management with an effective tool, to attract investors towards its portfolio.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) gained 44.12% in terms of its share value, during the October 14 trading session, to reach a close at $1.96 per share. The stock had a trade volume of 20.33 million.